A multimodal fusion model integrating Vision Transformer, radiomics, and clinical features for predicting bone metastasis in prostate cancer - Scorecard - MDSpire
Advertisement
A multimodal fusion model integrating Vision Transformer, radiomics, and clinical features for predicting bone metastasis in prostate cancer
Clinical Scorecard: A Comprehensive Fusion Approach Combining Vision Transformer, Radiomics, and Clinical Data for Predicting Bone Metastasis in Prostate Cancer
At a Glance
Category
Detail
Condition
Bone Metastasis in Prostate Cancer
Key Mechanisms
Integration of Vision Transformer, radiomics, and clinical features for prediction
Target Population
Patients with pathologically confirmed prostate cancer
Care Setting
Clinical decision-making and prognostic evaluation
Key Highlights
Model_Fusion achieved AUC of 0.944 in training and 0.894 in validation sets.
Model_ViT outperformed single-modal models in predicting bone metastasis.
Decision curve analysis indicated higher net benefit for Model_Fusion.
SHAP analysis showed ViT's predicted probability was the most influential in Model_Fusion.
Guideline-Based Recommendations
Diagnosis
Use of MRI and radiomics for enhanced detection of bone metastasis.
Management
Focus on palliative care, androgen deprivation therapy, chemotherapy, and radiotherapy for patients with bone metastasis.
Monitoring & Follow-up
Regular assessment of imaging and clinical features to evaluate bone metastasis status.
Risks
Patients with bone metastasis have poorer prognoses and higher mortality rates.
Patient & Prescribing Data
Patients diagnosed with prostate cancer and suspected bone metastasis.
Multimodal fusion models may guide personalized treatment decisions.
Clinical Best Practices
Implement advanced imaging techniques for early detection of bone metastasis.
Utilize multimodal approaches for comprehensive assessment of prostate cancer.
